Catalyst Investment Management’s AbbVie ABBV Stock Holding History

Catalyst Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$266K	Hold	1,058	–	–	0.24%	62
2026 Q1	$220K	Hold	1,058	–	–	0.24%	62
2025 Q4	$242K	Buy	+1,058	New	+$241K	0.23%	66

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Catalyst Investment Management's ABBV Position: Q2 2026 in Review

Catalyst Investment Management held its AbbVie (ABBV) position steady in Q2 2026 at 1,058 shares worth $266K. The position accounts for 0.24% of the portfolio, ranked #62.

Catalyst Investment Management first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Catalyst Investment Management held 1,058 shares of AbbVie worth $266K as of Q2 2026.
Catalyst Investment Management left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.24% of Catalyst Investment Management's portfolio in Q2 2026, its #62 holding.
Catalyst Investment Management first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Catalyst Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.